 |
|
Dehydroepiandrosterone Sulfate Causes Proliferation of Estrogen Receptor–Positive Breast Cancer Cells Despite Treatment With Fulvestrant
Kristine E. Calhoun, MD;
Rodney F. Pommier, MD;
Patrick Muller, BS;
William S. Fletcher, MD;
SuEllen Toth-Fejel, PhD
Arch Surg. 2003;138:879-883.
Hypothesis Dehydroepiandrosterone sulfate (DHEA-S) causes a proliferation of estrogen receptor (ER)–positive breast cancer cells, even with tamoxifen citrate blockade. The ER antagonist ICI 182 780 (fulvestrant) will more effectively stop the proliferative effect of DHEA-S on breast cancer cells.
Design Examination of in vitro breast cancer cell growth in the presence of fulvestrant and DHEA-S.
Setting Surgical oncology research laboratory.
Interventions The ER-positive and ER-negative breast cancer cells were pretreated with fulvestrant and stimulated with 900 µg/dL (22.8 µmol/L) of DHEA-S.
Main Outcome Measures Assays using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, thiazolyl blue, were performed on the third, fifth, and seventh days poststimulation and permitted the calculation of growth percent change.
Results The ER-positive and progesterone receptor–positive cells demonstrated universal proliferation of 107% by day 7 when treated with fulvestrant, regardless of the dose. The ER-negative and progesterone receptor–negative cells demonstrated growth inhibition.
Conclusions The DHEA-S circumvented fulvestrant inhibition and caused ER-positive breast cancer cell growth.
From the Division of Surgical Oncology, Department of General Surgery, Oregon Health and Sciences University, Portland.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Prepubertal Unilateral Fibrous Hyperplasia of the Labium Majus: Report of Eight Cases and Review of the Literature
Altchek et al.
Obstet Gynecol 2007;110:103-108.
ABSTRACT
| FULL TEXT
|
